Dual-action glaucoma drops now approved in U.S.

The FDA has approved latanoprostene bunod (Vyzulta), a nitric oxide-donating prostaglandin analog, for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
Source: Daily Dose of Eye Care

https://www.lvcenter4sight.com/dual-action-glaucoma-drops-now-approved-in-u-s/

Comments

Popular posts from this blog

Week in review: Pay raise, Von’s Vision, gonio-<em>what?</em>

Patch with Microneedles Could Replace Eye Injections

Incidence of eyelid SCC appears to be rising